Dr. Dalton on the Future Treatment of Gynecologic Malignancies

Heather Dalton, MD
Published: Wednesday, May 31, 2017



Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the future of treatment for gynecologic malignancies.

Dalton believes that platinum-based therapy and taxanes will remain the backbone of treatment for this disease. However, with the newest knowledge of BRCA and PARP inhibitors, she says, this landscape will hopefully have a stronger maintenance strategy.
 


Heather Dalton, MD, gynecologic oncologist, Arizona Oncology, discusses the future of treatment for gynecologic malignancies.

Dalton believes that platinum-based therapy and taxanes will remain the backbone of treatment for this disease. However, with the newest knowledge of BRCA and PARP inhibitors, she says, this landscape will hopefully have a stronger maintenance strategy.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x